On November 12, 2024, Conduit Pharmaceuticals Inc. disclosed that its previously issued unaudited financial statements for the first and second quarters of 2024 should not be relied upon. This announcement came after the company, in consultation with its advisors and its independent accounting firm Marcum LLP, identified a need to reclassify its deferred commission payable from a long-term liability to a current liability. The reclassification affects the balance sheets for the periods ending March 31, 2024, and June 30, 2024, but does not impact the total liabilities reported for those dates. Conduit Pharmaceuticals will amend its Quarterly Reports on Form 10-Q for the affected periods to reflect the restatement. The company's management and the Audit Committee have discussed these issues with Marcum LLP.

On November 12, 2024, Conduit Pharmaceuticals Inc. disclosed that its previously issued unaudited financial statements for the first and second quarters of 2024 should not be relied upon. This announcement came after the company, in consultation with its advisors and its independent accounting firm Marcum LLP, identified a need to reclassify its deferred commission payable from a long-term liability to a current liability. The reclassification affects the balance sheets for the periods ending March 31, 2024, and June 30, 2024, but does not impact the total liabilities reported for those dates. Conduit Pharmaceuticals will amend its Quarterly Reports on Form 10-Q for the affected periods to reflect the restatement. The company's management and the Audit Committee have discussed these issues with Marcum LLP.